All In Biotech

Drug Trial Radar · NCT01569295

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Last checked: Nov 19, 2026Latest source record: Mar 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

Jun 15, 2012

Primary completion

Jun 10, 2019

Study completion Jun 10, 2019

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Apr 3, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • IdelalisibDrug

    Idelalisib 150 mg administered orally twice daily

  • RituximabDrug

    Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions

  • BendamustineDrug

    Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions

  • Placebo to match idelalisibDrug

    Placebo to match idelalisib administered orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to 84 months

Locations

106 sites in 18 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama

  • UCLA Medical Center

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • University of Florida

    Gainesville, Florida

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Summit Medical Group, P.A.

    Morristown, New Jersey

  • North Shore University Hospital

    Manhasset, New York

  • Long Island Jewish Medical Center

    New Hyde Park, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Willamette Valley Cancer Center

    Eugene, Oregon

  • Charleston Hematology Oncology

    Charleston, South Carolina

  • Texas Oncology

    Austin, Texas

  • Texas Oncology PA

    Dallas, Texas

  • Texas Oncology

    Fort Worth, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Cancer Care Northwest, US Oncology

    Spokane, Washington

  • Virginia Cancer Specialists, PC

    Vancouver, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Princess Alexandra Hospital

    Woolloongabba, Australia

  • St Vincent's Hospital - Sydney

    Darlinghurst, New South Wales, Australia

  • Gosford Hospital

    Gosford, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Monash Medical Centre - Clayton Campus

    Clayton, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg

    Antwerp, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Cancer Care Manitoba

    Winnipeg, Manitoba, Canada

  • Clinical Hospital "Dubrava"

    Zagreb, Croatia

  • Klinichki Bolnicki Centar-Zagreb

    Zagreb, Croatia

  • University Hospital Merkur

    Zagreb, Croatia

  • Fakultni nemocnice Brno

    Brno, Czechia

  • Fakultní nemocnice Hradec Králové

    Hradec Králové, Czechia

  • Fakultni nemocnice Ostrava

    Ostrava, Czechia

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.